Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer

Tschoep-Lechner, Katharina Elisabeth; Milani, Valeria; Berger, Frank; Dieterle, Nelli; Abdel-Rahman, S.; Salat, Christoph; Issels, Rolf D.

doi:10.3109/02656736.2012.740764

Cited by 40 publications

(38 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such measures can be applied with the use of hyperthermia; if the search for application sites for hyperthermia is successful, this treatment can provide benefits for cancer patients whose performance status is satisfactory (21).…”

Section: Discussionmentioning

confidence: 99%

Treatment outcomes of concurrent hyperthermia and chemoradiotherapy for pancreatic cancer: Insights into the significance of hyperthermia treatment

et al. 2017

View full text Add to dashboard Cite

Abstract.Patients with locally advanced unresectable pancreatic cancer (LAUPC) have a poor prognosis. In addition their quality of life impaired by cancer pain and biliary tract infections. Therefore, multimodality therapy and selection of optimal treatment methods are essential for achieving prolonged survival. The present study investigated the significance of using hyperthermia concurrently with multimodality therapy to improve treatment outcomes in patients with LAUPC. In total, 13 patients receiving concurrent hyperthermia and chemoradiotherapy (HCR) or chemoradiotherapy (CR) alone for LAUPC between 2002 and 2013 were analyzed retrospectively. Of the 13 patients, 5 received concurrent HCR and 8 received CR. The chemotherapy regimens were 5-fluorouracil (5-FU) in 5 patients and gemcitabine hydrochloride (GEM) in the other 8. Patients who gave consent for hyperthermia treatment received GEM plus CR. The median overall survival period for all patients was 12 months and the 1-year survival rate was 55%; the corresponding values were 12 months and 57% in the GEM CR group, and 15 months and 80% in the HCR group. Univariate analyses was perfomed to identify factors predicting recurrence after treatment. The potential prognostic factors analyzed were: Age, sex, performance status, location, tumor size, the tumor marker CA 19-9, total radiation dose, chemotherapy and hyperthermia. Univariate analysis for factors associated with outcomes revealed a significant difference favoring the HCR group [relative risk=15.97 (95% confidence interval: 12.87-19.83) P=0.021]. In conclusion, hyperthermia merits active recommendation to pancreatic cancer patients who have a positive attitude toward this treatment and whose performance status is satisfactory.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment outcomes of concurrent hyperthermia and chemoradiotherapy for pancreatic cancer: Insights into the significance of hyperthermia treatment

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Randomised clinical trials are clearly [54]. c Only patients with available CT scans were included [64]. d The three studies that did not report response are excluded from the total number of patients.…”

Section: Discussionmentioning

confidence: 99%

“…Locoregional hyperthermia was used in eight studies, with heating of tumour and surrounding tissue either radiative (using radiofrequency waves; 63 patients) [62,64] or capacitive (using electrodes; 126 patients) [53,58,60,63,65,66]. Treatment times varied from 40-60 min.…”

Section: Patient Characteristics and Treatment Regimensmentioning

confidence: 99%

See 1 more Smart Citation

The clinical benefit of hyperthermia in pancreatic cancer: a systematic review

Horst

Versteijne

Besselink

et al. 2017

International Journal of Hyperthermia

View full text Add to dashboard Cite

Objective: In pancreatic cancer, which is therapy resistant due to its hypoxic microenvironment, hyperthermia may enhance the effect of radio(chemo)therapy. The aim of this systematic review is to investigate the validity of the hypothesis that hyperthermia added to radiotherapy and/or chemotherapy improves treatment outcome for pancreatic cancer patients. Methods and materials: We searched MEDLINE and Embase, supplemented by handsearching, for clinical studies involving hyperthermia in pancreatic cancer patients. The quality of studies was evaluated using the Oxford Centre for Evidence-Based Medicine levels of evidence. Primary outcome was treatment efficacy; we calculated overall response rate and the weighted estimate of the population median overall survival (m p ) and compared these between hyperthermia and control cohorts. Results: Overall, 14 studies were included, with 395 patients with locally advanced and/or metastatic pancreatic cancer of whom 248 received hyperthermia. Patients were treated with regional (n ¼ 189), intraoperative (n ¼ 39) or whole-body hyperthermia (n ¼ 20), combined with chemotherapy, radiotherapy or both. Quality of the studies was low, with level of evidence 3 (five studies) and 4. The six studies including a control group showed a longer m p in the hyperthermia groups than in the control groups (11.7 vs. 5.6 months). Overall response rate, reported in three studies with a control group, was also better for the hyperthermia groups (43.9% vs. 35.3%). Conclusions: Hyperthermia, when added to chemotherapy and/or radiotherapy, may positively affect treatment outcome for patients with pancreatic cancer. However, the quality of the reviewed studies was limited and future randomised controlled trials are needed to establish efficacy. ARTICLE HISTORY

show abstract

“…German Study II (Tschoep-Lechner et al 2013) [33] This retrospective study starts out as a second line therapy after gemcitabine failure. Patients received gemcitabine 1,000 mg/m2 on day 1 combined with cisplatin 25 mg/m2 combined with non invasive loco-regional radiative heating on day 2 and 4, biweekly for 4 months.…”

Section: The German Study I (Hager Et Al 2006) [24]mentioning

confidence: 99%

Review: The Role of Hyperthermia in Treating Pancreatic Tumors

Roesch

Mueller-Huebenthal

2014

Indian J Surg Oncol

View full text Add to dashboard Cite

There is only marginal improvement in outcome of treating pancreatic cancer in the last two decades. Time to open up and have a fresh look at complementary adjuvant treatment options. Hyperthermia may be one such option. Hyperthermic intraperitoneal chemotherapy (HIPEC) predominantly as a intrasurgical procedure has already proved its justification. Non-invasive loco regional hyperthermia as complement to either chemo or radiation has not yet reached a comparable status of evidence. However the potential to eventually grow into such evidence is already clearly observable. This review presents the various methodologies available for hyperthermia, covers the initial clinical data that has been published and gives an outlook to what can be expected in the next 2-3 years to come. Hyperthermia has the potential to significantly prolong life expectancies and this while maintaining a satisfying quality of life!

show abstract

Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer

Cited by 40 publications

References 28 publications

Treatment outcomes of concurrent hyperthermia and chemoradiotherapy for pancreatic cancer: Insights into the significance of hyperthermia treatment

Treatment outcomes of concurrent hyperthermia and chemoradiotherapy for pancreatic cancer: Insights into the significance of hyperthermia treatment

The clinical benefit of hyperthermia in pancreatic cancer: a systematic review

Review: The Role of Hyperthermia in Treating Pancreatic Tumors

Contact Info

Product

Resources

About